BioMarin Pharmaceutical

About BioMarin Pharmaceutical

BioMarin Pharmaceutical is a global biotechnology company focused on developing and commercialising innovative biopharmaceuticals for serious diseases and medical conditions. Established in 1997, the company has made significant strides in the field of rare diseases, particularly those that affect children.

With a commitment to improving the lives of patients, BioMarin’s portfolio includes therapies for conditions such as phenylketonuria (PKU), achondroplasia, and other genetic disorders. The company employs cutting-edge science and technology to create treatments that address unmet medical needs.

BioMarin operates with a vision to be the world leader in the development of innovative biopharmaceuticals for rare diseases. Their mission is driven by a passion for patient care and a dedication to scientific excellence.

• Research and Development: BioMarin invests heavily in R&D to discover new therapies and improve existing ones.
• Global Reach: The company has a presence in multiple countries, ensuring access to its therapies worldwide.
• Patient-Centric Approach: BioMarin prioritises the needs of patients in every aspect of its operations.

Headquartered in the United States, BioMarin has expanded its operations globally, including a strong presence in the UK. The company is committed to ethical practices and compliance with regulatory standards, ensuring the safety and efficacy of its products.

Through collaboration with healthcare professionals, researchers, and patient advocacy groups, BioMarin aims to foster innovation and drive advancements in the treatment of rare diseases. The company’s dedication to improving patient outcomes is reflected in its ongoing efforts to develop new therapies and enhance existing treatment options.